Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Baudax Bio Inc

BXRX
Current price
0.012 USD -0.0001 USD (-0.86%)
Last closed 0.016 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 950 329 USD
Yield for 12 month -99.36 %
1Y
3Y
5Y
10Y
15Y
BXRX
21.11.2021 - 28.11.2021

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania. Address: 490 Lapp Road, Malvern, PA, United States, 19355

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24 USD

P/E ratio

Dividend Yield

Current Year

+1 269 000 USD

Last Year

+1 269 000 USD

Current Quarter

Last Quarter

+30 000 USD

Current Year

Last Year

-5 740 000 USD

Current Quarter

-43 000 USD

Last Quarter

-74 000 USD

Key Figures BXRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -34 761 000 USD
Operating Margin TTM -2759.89 %
PE Ratio
Return On Assets TTM -114.93 %
PEG Ratio
Return On Equity TTM -4704.21 %
Wall Street Target Price 24 USD
Revenue TTM 1 269 000 USD
Book Value -0.84 USD
Revenue Per Share TTM 0.32 USD
Dividend Share
Quarterly Revenue Growth YOY -22.5 %
Dividend Yield
Gross Profit TTM -5 740 000 USD
Earnings Share -94.13 USD
Diluted Eps TTM -94.13 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BXRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BXRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:40
Payout Ratio
Last Split Date 01.12.2022
Dividend Date

Stock Valuation BXRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.6339
Price Sales TTM 0.7489
Enterprise Value EBITDA -0.2569
Price Book MRQ 0.6815

Financials BXRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BXRX

For 52 weeks

0.011 USD 3.47 USD
50 Day MA 0.024 USD
Shares Short Prior Month 35 678
200 Day MA 0.29 USD
Short Ratio 0.19
Shares Short 493 562
Short Percent 3.9 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics